SuperworthPrecigen revenue PGEN
Sales by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $55M
- +6323% on a year earlier
- Fiscal year 2022
- $26.9M
- −52% on the year before
Precigen's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $55M, up 6323% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2022 | $26.9M | −52% |
| FY2021 | $55.9M | −46% |
| FY2020 | $103.2M | +14% |
| FY2019 | $90.7M | −44% |
| FY2018 | $160.6M | −31% |
| FY2017 | $231.2M | +21% |
| FY2016 | $190.9M | +10% |
| FY2015 | $173.6M | +141% |
| FY2014 | $71.9M | +203% |
| FY2013 | $23.8M | +72% |
| FY2012 | $13.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $55M | +6323% | n/a | |
| Q1 FY26 | $23.3M | +1634% | n/a | |
| Q2 FY25 | $856K | n/a | n/a | |
| Q1 FY25 | $1.3M | n/a | n/a | |
| Q2 FY23 | $1.8M | −39% | $22.1M | |
| Q1 FY23 | $1.9M | −66% | $23.2M | |
| Q4 FY22 | $1.8M | −93% | $26.9M | |
| Q3 FY22 | $16.7M | +402% | $49.4M | |
| Q2 FY22 | $2.9M | −24% | $36M | |
| Q1 FY22 | $5.5M | −78% | $36.9M | |
| Q4 FY21 | $24.2M | +25% | $55.9M | |
| Q3 FY21 | $3.3M | −86% | $51M |
Against its peers
Companies in Drug Manufacturers - General nearest Precigen's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| PGENPrecigen | n/m | |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| NRIXNurix Therapeutics | $701.9M | |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| ANABAnaptysbio | n/m | |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| OGNOrganon | $6.1B | −2% a year |
| LQDALiquidia | $450.9M | |
| ARQTArcutis Biotherapeutics | $464M | +76% a year |
| Peer median | $959.9M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Precigen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.